Lixte Biotechnology Raises $4.3 Million to Advance Cancer Treatment Development
核心洞察
Lixte Biotechnology Holdings (搜索) completed a $4.3 million registered direct offering priced at market under Nasdaq rules to fund cancer treatment development.
The company is advancing LB-100, a first-in-class PP2A (搜索) inhibitor that has demonstrated tolerability in cancer patients at doses associated with anti-cancer activity.
Proof-of-concept clinical trials are currently underway for ovarian clear cell carcinoma and metastatic colon cancer using the company's novel activation lethality approach.
Lixte Biotechnology Holdings (搜索), Inc. (NASDAQ: LIXT) announced the completion of a $4.3 million registered direct offering with accredited investors on December 18, 2025, providing crucial funding for the clinical-stage pharmaceutical company's cancer treatment development programs.
The Boca Raton-based biotech company priced the offering at $4.09 per Common Unit under Nasdaq market rules, selling 1,051,342 Common Units or Pre-Funded Units. Each unit consists of one share of Common Stock or one Pre-Funded Warrant, plus one Common Warrant to purchase one share of Common Stock at an exercise price of $3.96. The Common Warrants are exercisable immediately and expire 60 months after issuance.
Lead Compound Shows Promise in Clinical Development
Lixte's primary focus centers on LB-100, a first-in-class PP2A (搜索) inhibitor that represents a pioneering effort in activation lethality, an entirely new field of cancer biology. The company has demonstrated that LB-100 is well-tolerated in cancer patients at doses associated with anti-cancer activity, according to clinical data.
Based on extensive published preclinical data, LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer. The compound is part of Lixte's new treatment paradigm covered by a comprehensive patent portfolio.
Active Clinical Trial Portfolio
The company is currently conducting proof-of-concept clinical trials for two key indications: ovarian clear cell carcinoma and metastatic colon cancer. These trials represent the clinical validation of Lixte's novel approach to cancer treatment through activation lethality mechanisms.
Funding Structure and Timeline
Spartan Capital Securities (搜索), LLC served as the exclusive placement agent for the offering, with Sichenzia Ross Ference Carmel LLP acting as counsel to the company. The transaction was expected to close on or about December 19, 2025, subject to customary closing conditions.
The company plans to use the net proceeds from the offering, combined with existing cash, for general corporate purposes and working capital to support its ongoing clinical development programs.
Regulatory Framework
The registered direct offering was conducted pursuant to an effective shelf registration statement on Form S-3 (No. 333-278874) previously filed with the U.S. Securities and Exchange Commission and declared effective on May 2, 2024. A final prospectus supplement and accompanying prospectus describing the offering terms will be filed with the SEC and made available through standard regulatory channels.